Goldman Sachs reiterates Sell rating on Rocket Pharmaceuticals stock

Rocket Pharmaceuticals (RCKT) announced the FDA has lifted a clinical hold on its pivotal Phase 2 study for RP-A501 in Danon disease, allowing the trial to resume with an adjusted lower dose. This critical development, which prompted BofA Securities to upgrade RCKT to Buy with a $10 price target, contrasts with Goldman Sachs' reiterated Sell rating and $2 target, reflecting divergent analyst views despite the stock's significant year-over-year depreciation. Concurrently, RCKT is undergoing a 30% workforce reduction to strategically focus on its core cardiovascular gene therapy programs, including Danon disease, aiming to streamline its pipeline advancement and resource allocation.

Analysis

Rocket Pharmaceuticals (RCKT) has experienced a significant clinical de-risking event with the FDA's decision to lift the hold on its pivotal Phase 2 study for RP-A501 in Danon disease. The trial's resumption, albeit at a lower dose of 3.8E13 GC/kg, provides a path forward for a key pipeline asset, but has elicited sharply divergent reactions from analysts. BofA Securities upgraded the stock to Buy with a $10.00 price target, citing a "positive surprise," whereas Goldman Sachs reiterated its Sell rating and $2.00 target, highlighting deep-seated uncertainty despite the news. This wide analyst target range, from $2 to $16, comes after the stock has already fallen nearly 85% over the past year. Concurrently, RCKT is undergoing a strategic reorganization involving a 30% workforce reduction to concentrate resources on its cardiovascular gene therapy programs. The company's financial position appears solid, with a current ratio of 6.39 and more cash than debt, suggesting it has the runway to fund these prioritized clinical activities.

Key Decisions for Investors

• Given the starkly divergent analyst price targets ranging from $2 to $10, investors should treat RCKT as a high-risk, event-driven asset where the positive FDA news is not uniformly seen as a definitive turning point.
• The primary focus should now be on the forthcoming clinical data from the next three patients in the resumed Phase 2 trial, as this will be the next major catalyst and will validate the viability of the new lower-dose regimen.
• Consider the company's strong liquidity and recent strategic restructuring as factors that enhance its financial runway, potentially providing a cushion for investors with a long-term, high-risk tolerance who are bullish on the underlying gene therapy platform.
• Given the stock's extreme volatility and the remaining clinical uncertainties, any position should be sized appropriately to reflect the binary nature of a clinical-stage biotechnology investment.